Dr Andrew Thompson is a Principal Research Fellow and Associate Professor at Orygen, the Centre for Youth Mental Health at the University of Melbourne, Australia. He is the lead psychiatrist for the EPPIC early psychosis service and the National headspace Early Psychosis program in Australia and is currently head of clinical psychosis research at Orygen. He also retains a position as Associate Professor at the University of Warwick in the UK.Andrew trained in medicine at the University of Oxford and London and in psychiatry in Nottingham and Bristol. He has an MD in clinical psychiatry from the University of London. He has worked in early psychosis practice and research for over 15 years in both the UK and Australia. He was previously clinical lead for the PACE at risk for psychosis clinic in Melbourne and has been involved in a number of research projects through this clinic and through his work at the University of Bristol and the University of Warwick.Andrew’s research interests include clinical risk factors for the development of psychosis and psychotic symptoms, novel treatments (including technology) in emerging or early psychosis, predictors of outcome in early psychosis and systems of care and prevention approaches in youth mental health. Dr Matthew Broome is a Senior Clinical Research Fellow at the Department of Psychiatry, University of Oxford, and a Consultant Psychiatrist at the Early Intervention in Psychosis Service, Oxford. He trained in medicine at the University of Birmingham and in Psychiatry at the Maudsley hospital (where he worked at the at risk for psychosis clinic (OASIS). He has previously been a Lecturer at the Institute of Psychiatry and an Associate Clinical Professor at The University of Warwick. He has previously edited books on subjects such as phenomenology and the interface between psychiatry and philosophy and has published over 100 research papers mostly relating to at risk for psychosis groups.

Select Guide Rating

• 1. Historical perspectives on psychosis riskCRISTINA MEI AND PATRICK D. MCGORRY2. Principles of risk, screening, and prevention in psychiatryEMMA SONESON, JESUS PEREZ, AND PETER B. JONESI - Risk paradigms3. At-risk mental statesALISON R. YUNG4. Subjective disturbances in emerging psychosis: basic symptoms and self-disturbancesFRAUKE SCHULTZE-LUTTER, CHANTAL MICHEL, RAHEL FL €UCKIGER, AND ANASTASIA THEODORIDOU5. Schizotypy, schizotypal personality, and psychosis riskNEUS BARRANTES-VIDAL, ANNA RACIOPPI, AND THOMAS R. KWAPIL6. Familial high risk and high-risk studiesLIANA ROMANIUK, STELLA W.Y. CHAN, ALIX MACDONALD, JESSIKA E. SUSSMANN, ANDREW M. MCINTOSH, HEATHER C. WHALLEY, AND STEPHEN M. LAWRIE7. Psychotic-like experiences in the general populationCOLM HEALY AND MARY CANNON8. 22q11.2 deletion syndrome: a neurodevelopmental model of psychosisCORRADO SANDINI, STEPHAN ELIEZ, MAUDE SCHNEIDER, AND MARCO ARMANDOII - Specific areas and risk9. Neuroimaging studies in people at clinical high risk for psychosisGEORGE GIFFORD, ROB MCCUTCHEON, AND PHILIP MCGUIRE10. Genetic studies of psychosisHANNAH J. JONES, STANLEY ZAMMIT, AND JAMES T.R. WALTERS11. Immune processes and risk of psychosisADAM AL-DIWANI AND THOMAS ARTHUR NICHOLLS POLLAK12. Neurochemical models of psychosis risk and onsetDOMINIC OLIVER, GEMMA MODINOS, AND PHILIP MCGUIRE13. Clinical risk factors for psychosisASWIN RATHEESH, JESSICA A. HARTMANN, AND BARNABY NELSON14. Cognitive risk factors for psychosisKELLY ALLOTT AND ASHLEIGH LIN15. Society and risk of psychosisCRAIG MORGAN, TESSA ROBERTS, BRIAN O. DONOGHUE, AND ANDREW THOMPSON16. Is there sufficient evidence that cannabis use is a risk factor for psychosis?MARCO COLIZZI AND SAGNIK BHATTACHARYYAIII - Interventions17. The ethics of identifying and treating psychosis riskPAOLO CORSICO AND ILINA SINGHJEAN ADDINGTON, DANIJELA PISKULIC, DANIEL J. DEVOE, OLGA SANTESTEBAN-ECHARRI, AND JACQUELINE STOWKOWY19. Pharmacological intervention for people at risk of psychotic disorderE. BURKHARDT, K. LEOPOLD AND A. BECHDOLF20. International services for assessing and treating psychosis riskCHRISTY L.M. HUI, W.C. CHANG, SHERRY K.W. CHAN, EDWIN H.M. LEE, Y.N. SUEN, AND ERIC Y.H. CHEN21. New paradigms to study psychosis risk: clinical staging, pluripotency, and dynamic predictionRACHAEL SPOONER, JESSICA A. HARTMANN, PATRICK D. MCGORRY, AND BARNABY NELSON22. Future directions in risk researchNIKOLAI ALBERT, LOUISE BIRKEDAL GLENTHØJ, AND MERETE NORDENTOFT

Dr Andrew Thompson is a Principal Research Fellow and Associate Professor at Orygen, the Centre for Youth Mental Health at the University of Melbourne, Australia. He is the lead psychiatrist for the EPPIC early psychosis service and the National headspace Early Psychosis program in Australia and is currently head of clinical psychosis research at Orygen. He also retains a position as Associate Professor at the University of Warwick in the UK.Andrew trained in medicine at the University of Oxford and London and in psychiatry in Nottingham and Bristol. He has an MD in clinical psychiatry from the University of London. He has worked in early psychosis practice and research for over 15 years in both the UK and Australia. He was previously clinical lead for the PACE at risk for psychosis clinic in Melbourne and has been involved in a number of research projects through this clinic and through his work at the University of Bristol and the University of Warwick.Andrew’s research interests include clinical risk factors for the development of psychosis and psychotic symptoms, novel treatments (including technology) in emerging or early psychosis, predictors of outcome in early psychosis and systems of care and prevention approaches in youth mental health. Dr Matthew Broome is a Senior Clinical Research Fellow at the Department of Psychiatry, University of Oxford, and a Consultant Psychiatrist at the Early Intervention in Psychosis Service, Oxford. He trained in medicine at the University of Birmingham and in Psychiatry at the Maudsley hospital (where he worked at the at risk for psychosis clinic (OASIS). He has previously been a Lecturer at the Institute of Psychiatry and an Associate Clinical Professor at The University of Warwick. He has previously edited books on subjects such as phenomenology and the interface between psychiatry and philosophy and has published over 100 research papers mostly relating to at risk for psychosis groups.

Select Guide Rating

• 1. Historical perspectives on psychosis riskCRISTINA MEI AND PATRICK D. MCGORRY2. Principles of risk, screening, and prevention in psychiatryEMMA SONESON, JESUS PEREZ, AND PETER B. JONESI - Risk paradigms3. At-risk mental statesALISON R. YUNG4. Subjective disturbances in emerging psychosis: basic symptoms and self-disturbancesFRAUKE SCHULTZE-LUTTER, CHANTAL MICHEL, RAHEL FL €UCKIGER, AND ANASTASIA THEODORIDOU5. Schizotypy, schizotypal personality, and psychosis riskNEUS BARRANTES-VIDAL, ANNA RACIOPPI, AND THOMAS R. KWAPIL6. Familial high risk and high-risk studiesLIANA ROMANIUK, STELLA W.Y. CHAN, ALIX MACDONALD, JESSIKA E. SUSSMANN, ANDREW M. MCINTOSH, HEATHER C. WHALLEY, AND STEPHEN M. LAWRIE7. Psychotic-like experiences in the general populationCOLM HEALY AND MARY CANNON8. 22q11.2 deletion syndrome: a neurodevelopmental model of psychosisCORRADO SANDINI, STEPHAN ELIEZ, MAUDE SCHNEIDER, AND MARCO ARMANDOII - Specific areas and risk9. Neuroimaging studies in people at clinical high risk for psychosisGEORGE GIFFORD, ROB MCCUTCHEON, AND PHILIP MCGUIRE10. Genetic studies of psychosisHANNAH J. JONES, STANLEY ZAMMIT, AND JAMES T.R. WALTERS11. Immune processes and risk of psychosisADAM AL-DIWANI AND THOMAS ARTHUR NICHOLLS POLLAK12. Neurochemical models of psychosis risk and onsetDOMINIC OLIVER, GEMMA MODINOS, AND PHILIP MCGUIRE13. Clinical risk factors for psychosisASWIN RATHEESH, JESSICA A. HARTMANN, AND BARNABY NELSON14. Cognitive risk factors for psychosisKELLY ALLOTT AND ASHLEIGH LIN15. Society and risk of psychosisCRAIG MORGAN, TESSA ROBERTS, BRIAN O. DONOGHUE, AND ANDREW THOMPSON16. Is there sufficient evidence that cannabis use is a risk factor for psychosis?MARCO COLIZZI AND SAGNIK BHATTACHARYYAIII - Interventions17. The ethics of identifying and treating psychosis riskPAOLO CORSICO AND ILINA SINGHJEAN ADDINGTON, DANIJELA PISKULIC, DANIEL J. DEVOE, OLGA SANTESTEBAN-ECHARRI, AND JACQUELINE STOWKOWY19. Pharmacological intervention for people at risk of psychotic disorderE. BURKHARDT, K. LEOPOLD AND A. BECHDOLF20. International services for assessing and treating psychosis riskCHRISTY L.M. HUI, W.C. CHANG, SHERRY K.W. CHAN, EDWIN H.M. LEE, Y.N. SUEN, AND ERIC Y.H. CHEN21. New paradigms to study psychosis risk: clinical staging, pluripotency, and dynamic predictionRACHAEL SPOONER, JESSICA A. HARTMANN, PATRICK D. MCGORRY, AND BARNABY NELSON22. Future directions in risk researchNIKOLAI ALBERT, LOUISE BIRKEDAL GLENTHØJ, AND MERETE NORDENTOFT

Dr Andrew Thompson is a Principal Research Fellow and Associate Professor at Orygen, the Centre for Youth Mental Health at the University of Melbourne, Australia. He is the lead psychiatrist for the EPPIC early psychosis service and the National headspace Early Psychosis program in Australia and is currently head of clinical psychosis research at Orygen. He also retains a position as Associate Professor at the University of Warwick in the UK.Andrew trained in medicine at the University of Oxford and London and in psychiatry in Nottingham and Bristol. He has an MD in clinical psychiatry from the University of London. He has worked in early psychosis practice and research for over 15 years in both the UK and Australia. He was previously clinical lead for the PACE at risk for psychosis clinic in Melbourne and has been involved in a number of research projects through this clinic and through his work at the University of Bristol and the University of Warwick.Andrew’s research interests include clinical risk factors for the development of psychosis and psychotic symptoms, novel treatments (including technology) in emerging or early psychosis, predictors of outcome in early psychosis and systems of care and prevention approaches in youth mental health. Dr Matthew Broome is a Senior Clinical Research Fellow at the Department of Psychiatry, University of Oxford, and a Consultant Psychiatrist at the Early Intervention in Psychosis Service, Oxford. He trained in medicine at the University of Birmingham and in Psychiatry at the Maudsley hospital (where he worked at the at risk for psychosis clinic (OASIS). He has previously been a Lecturer at the Institute of Psychiatry and an Associate Clinical Professor at The University of Warwick. He has previously edited books on subjects such as phenomenology and the interface between psychiatry and philosophy and has published over 100 research papers mostly relating to at risk for psychosis groups.

Select Guide Rating

• 1. Historical perspectives on psychosis riskCRISTINA MEI AND PATRICK D. MCGORRY2. Principles of risk, screening, and prevention in psychiatryEMMA SONESON, JESUS PEREZ, AND PETER B. JONESI - Risk paradigms3. At-risk mental statesALISON R. YUNG4. Subjective disturbances in emerging psychosis: basic symptoms and self-disturbancesFRAUKE SCHULTZE-LUTTER, CHANTAL MICHEL, RAHEL FL €UCKIGER, AND ANASTASIA THEODORIDOU5. Schizotypy, schizotypal personality, and psychosis riskNEUS BARRANTES-VIDAL, ANNA RACIOPPI, AND THOMAS R. KWAPIL6. Familial high risk and high-risk studiesLIANA ROMANIUK, STELLA W.Y. CHAN, ALIX MACDONALD, JESSIKA E. SUSSMANN, ANDREW M. MCINTOSH, HEATHER C. WHALLEY, AND STEPHEN M. LAWRIE7. Psychotic-like experiences in the general populationCOLM HEALY AND MARY CANNON8. 22q11.2 deletion syndrome: a neurodevelopmental model of psychosisCORRADO SANDINI, STEPHAN ELIEZ, MAUDE SCHNEIDER, AND MARCO ARMANDOII - Specific areas and risk9. Neuroimaging studies in people at clinical high risk for psychosisGEORGE GIFFORD, ROB MCCUTCHEON, AND PHILIP MCGUIRE10. Genetic studies of psychosisHANNAH J. JONES, STANLEY ZAMMIT, AND JAMES T.R. WALTERS11. Immune processes and risk of psychosisADAM AL-DIWANI AND THOMAS ARTHUR NICHOLLS POLLAK12. Neurochemical models of psychosis risk and onsetDOMINIC OLIVER, GEMMA MODINOS, AND PHILIP MCGUIRE13. Clinical risk factors for psychosisASWIN RATHEESH, JESSICA A. HARTMANN, AND BARNABY NELSON14. Cognitive risk factors for psychosisKELLY ALLOTT AND ASHLEIGH LIN15. Society and risk of psychosisCRAIG MORGAN, TESSA ROBERTS, BRIAN O. DONOGHUE, AND ANDREW THOMPSON16. Is there sufficient evidence that cannabis use is a risk factor for psychosis?MARCO COLIZZI AND SAGNIK BHATTACHARYYAIII - Interventions17. The ethics of identifying and treating psychosis riskPAOLO CORSICO AND ILINA SINGHJEAN ADDINGTON, DANIJELA PISKULIC, DANIEL J. DEVOE, OLGA SANTESTEBAN-ECHARRI, AND JACQUELINE STOWKOWY19. Pharmacological intervention for people at risk of psychotic disorderE. BURKHARDT, K. LEOPOLD AND A. BECHDOLF20. International services for assessing and treating psychosis riskCHRISTY L.M. HUI, W.C. CHANG, SHERRY K.W. CHAN, EDWIN H.M. LEE, Y.N. SUEN, AND ERIC Y.H. CHEN21. New paradigms to study psychosis risk: clinical staging, pluripotency, and dynamic predictionRACHAEL SPOONER, JESSICA A. HARTMANN, PATRICK D. MCGORRY, AND BARNABY NELSON22. Future directions in risk researchNIKOLAI ALBERT, LOUISE BIRKEDAL GLENTHØJ, AND MERETE NORDENTOFT